Quick Answer
Akebia Therapeutics, Inc. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2025.
Akebia Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.02 | +93.9% |
| 2024 | -$0.33 | -17.9% |
| 2023 | -$0.28 | +46.2% |
| 2022 | -$0.52 | +69.4% |
| 2021 | -$1.70 | +38.6% |
| 2020 | -$2.77 | -17.4% |
| 2019 | -$2.36 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | +100.0% | — |
| June 30, 2025 | $0.00 | +100.0% | -100.0% |
| March 31, 2025 | $0.03 | +133.3% | +130.0% |
| September 30, 2024 | -$0.10 | -25.0% | -150.0% |
| June 30, 2024 | -$0.04 | +33.3% | +55.6% |
| March 31, 2024 | -$0.09 | +40.0% | -12.5% |
| September 30, 2023 | -$0.08 | +72.4% | -33.3% |
| June 30, 2023 | -$0.06 | -140.0% | +60.0% |
- Akebia Therapeutics, Inc. showed an increase of +93.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Akebia Therapeutics, Inc.’s diluted eps has grown by 99.2% (from $2.36 per share (loss) to $0.02 per share (loss)).
- The most recent figure is from Akebia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: